在阿尔茨海默氏病中识别与代谢相关的亚型和特征基因
Piaopiao Lian1, Xing Cai2, Cailin Wang1
1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Journal of translational medicine
|September 15, 2023
概括
研究人员根据新陈代谢确定了不同的阿尔茨海默病 (AD) 亚型,揭示了与疾病进展相关的关键代谢基因. 这些发现为开发针对阿尔茨海默病 (AD) 的个性化疗法提供了潜力.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 代谢学 代谢学 代谢学
背景情况:
- 阿尔茨海默病 (AD) 的发病过程复杂,并未得到充分理解.
- 代谢功能障碍越来越被认为是AD病理生理学的重要因素.
- 根据代谢资料确定AD亚型对于理解疾病异质性至关重要.
研究的目的:
- 根据代谢基因表达来识别阿尔茨海默氏症 (AD) 的不同亚型.
- 确定与AD进展和临床结果相关的关键代谢基因.
- 探索这些基因在开发AD新型诊断和治疗策略方面的潜力.
主要方法:
- 用于阿尔茨海默氏病 (AD) 的基因表达全集 (GEO) 数据集.
- 应用共识聚类来识别代谢性AD子类.
- 使用权重基因相关联网络分析 (WGCNA) 和机器学习来识别特征基因.
- 使用定量逆转录聚合酶链反应 (qRT-PCR) 验证的基因表达和诊断值.
主要成果:
- 确定了三种与代谢相关的AD子类 (MCA,MCB,MCC).
- 该MCA子类显示高AD进展签名,与改变的糖解和酸盐循环基因表达.
- 八个特征基因 (GFAP,CYB5R3,DARS,KIAA0513,EZR,KCNC1,COLEC12,TST) 被确定与阿尔茨海默病的进展有很强的关联.
- 一个基于这些特征基因的诺莫格拉姆模型证明了AD患者的临床实用性.
结论:
- 代谢功能障碍是导致阿尔茨海默病 (AD) 的关键因素.
- 基于新陈代谢的AD分子子类为个性化治疗方法提供了新的视角.
- 已识别的特征基因与阿尔茨海默病的进展有很强的相关性,并有可能用于诊断和治疗应用.
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


